Open‑label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety

Sponsor ID
331-201-00376
Clinicaltrials.gov ID
EudraCT ID
N/A
EUCTIS ID
N/A
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information
N/A
Terminated/Withdrawn
Sponsor ID
331-201-00376

Study Summary

The purpose of this study is to use fMRI to evaluate the effects of brexpiprazole as add-on therapy to antidepressants on brain connectivity in individuals with MDD and symptoms of anxiety, aged 18 to 65.

Additional Study Details

Phase
Phase 4
Study Drug
Drug: Brexpiprazole
Type
Interventional
Masking
None (Open Label)
Estimated Enrollment
N/A
Additional Study Details

Inclusion and Exclusion Criteria

Inclusion Criteria

  • * 18 to 65 year of age
  • * Major Depressive Disorder (MDD) with symptoms of anxiety

Exclusion Criteria

  • * Contraindicated to perform fMRI scan
  • * Previous exposure to brexpiprazole

Locations

No locations found.